Atria Investments Inc Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Atria Investments Inc lifted its stake in Johnson & Johnson (NYSE:JNJ) by 1.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 199,819 shares of the company’s stock after purchasing an additional 2,619 shares during the quarter. Johnson & Johnson accounts for approximately 0.6% of Atria Investments Inc’s holdings, making the stock its 24th biggest position. Atria Investments Inc’s holdings in Johnson & Johnson were worth $30,972,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Moneta Group Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Geode Capital Management LLC grew its stake in shares of Johnson & Johnson by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock valued at $8,456,643,000 after purchasing an additional 294,671 shares during the period. Morgan Stanley grew its stake in shares of Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after acquiring an additional 3,849,148 shares during the period. Finally, Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $4,609,399,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $166.25 on Monday. The stock’s fifty day moving average is $166.68 and its two-hundred day moving average is $161.48. The company has a market capitalization of $432.08 billion, a PE ratio of 33.65, a price-to-earnings-growth ratio of 2.79 and a beta of 0.54. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. Johnson & Johnson’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.59 EPS. As a group, analysts expect that Johnson & Johnson will post 10.75 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.86%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on JNJ shares. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Atlantic Securities boosted their price objective on Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. Barclays boosted their price objective on Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a research note on Monday, July 24th. Stifel Nicolaus boosted their price target on Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $187.00 price target on shares of Johnson & Johnson in a report on Friday, July 21st. Eight investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $171.80.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at $10,549,440. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,163 shares of company stock worth $7,928,856. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.